Compare Merck & Co., Inc. (MRK) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Standard Lithium Ltd — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Standard Lithium Ltd trades at $2.27 (market cap $523.89M). The key difference: Merck & Co., Inc. is far larger — about 586.5× Standard Lithium Ltd's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| MRK | SLI | |
|---|---|---|
Market Cap | $307.25B | $523.89M |
Sector | Health | Basic Materials |
52-Week High | $129.52 | $5.65 |
52-Week Low | $77.60 | $2.15 |
Enterprise Value | $350.66B | $383.09M |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Standard Lithium (SLI) trades at $2.15, down 4.87% today, reflecting ongoing bearish technical momentum despite a 100% buy rating from 3 analysts. The stock shows negative profitability with ROE at -16.6% and net income of -$48.40M in 2025, though recent Q1 2026 earnings beat expectations. Key developments include progress on its Arkansas lithium project, a $225M DOE grant, and a binding offtake agreement with Trafigura, positioning the company for future production by 2029.
The investment case hinges on successful project execution and lithium market dynamics, offering high growth potential but carrying significant operational and funding risks. Current negative cash flows and reliance on financing highlight volatility, making it suitable for risk-tolerant investors betting on the energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
